MEIP Stock Summary and Trading Ideas (Mei Pharma | NASDAQ:MEIP)

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Mei Pharma trades on the NASDAQ stock market under the symbol MEIP.

As of February 28, 2025, MEIP stock price declined to $2.56 with 5,961 million shares trading.

MEIP has a market cap of $17.06 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MEIP traded as high as $44.04 and as low as $2.30.

The top ETF exchange traded funds that MEIP belongs to (by Net Assets): VTI, VXF, DFAT.

MEIP has underperformed the market in the last year with a price return of -39.0% while the SPY ETF gained +18.8%. MEIP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.6% and -4.8%, respectively, while the SPY returned -0.4% and -2.5%, respectively.

MEIP support price is $2.44 and resistance is $2.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEIP shares will trade within this expected range on the day.